Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer

NCT05215379 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

201

Enrollment

OTHER

Sponsor class

Conditions

Neoadjuvant Chemoradiation Therapy
Rectal Cancer
Immunotherapy
Microsatellite Instability Low

Interventions

DRUG: xintilimab injection
OTHER: Control

Sponsor

Changhai Hospital